UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | April 17, 2008 |
Cytokinetics, Incorporated
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-50633 | 94-3291317 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
280 East Grand Avenue, South San Francisco, California | 94080 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | (650) 624 - 3000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 17, 2008, Cytokinetics, Incorporated issued a press release announcing the selection of a development compound that is directed towards a molecular target in the skeletal sarcomere. This compound is a highly specific small molecule activator of the troponin complex, increasing its sensitivity to calcium, and subsequently leading to an increase in skeletal muscle contractility. This mechanism of action has demonstrated encouraging pharmacological activity in non-clinical models that may relate to potential treatment of diseases associated with aging and neuromuscular wasting. The potential drug candidate is the fifth development compound to emerge from the company’s research activities which have focused on discovering novel therapeutics directed towards cytoskeletal biology. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following Exhibit is filed as part of this Current Report on Form 8-K:
Exhibit No. Description
-----------------------
99.1 Press Release, dated April 17, 2008.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cytokinetics, Incorporated | ||||
April 17, 2008 | By: |
/s/ Sharon Surrey-Barbari
|
||
|
||||
Name: Sharon Surrey-Barbari | ||||
Title: Senior Vice President, Finance and Chief Financial Officer |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press release, dated April 17, 2008 |